Lantern Pharma, Inc. (LTRN) is a clinical-stage, AI-driven precision oncology company, not an ETF. Its small analyst coverage consists of two tracked price targets with a wide range of roughly $10 to $25, producing a calculated mean of $17.50. The most visible is Lake Street Capital Markets analyst Chad Messer, who has repeatedly reaffirmed a Buy rating and a $25 target (most recently in May 2026). A second analyst carries a materially lower target near $10. The resulting "Strong Buy" consensus reflects bullish conviction in the pipeline rather than agreement on valuation — the gap between the two targets underscores how binary the outcome is.
Lake Street's $25 figure is built almost entirely on LP-300, applying a 5x revenue multiple and a steep 50% annual discount rate to model a $294 million enterprise value, while assigning zero value to the rest of the pipeline. Importantly, these targets were set when the stock traded near $3 and have not been updated to reflect the subsequent collapse below $1.
LTRN recently traded near $0.47, near the bottom of its 52-week range of $0.45 to $4.34, with a market capitalization of roughly $7 million. Reaching the $17.50 central target would require upside of about 3,600% — a "very large" move by any standard. The company generates no commercial revenue and reported a trailing net loss near $18.7 million, with roughly $7.4 million in cash.
The theoretical path depends on clinical execution: positive data from the HARMONIC Phase 2 trial of LP-300, progress for LP-184 and LP-284, and ultimately regulatory milestones that could justify a re-rating. In practice, the shares would likely need a reverse split or a return above the $1 Nasdaq minimum-bid threshold simply to remain listed before any such re-rating could occur.
The stock is testing its 52-week low near $0.45, which now acts as the primary support level. The $1.00 Nasdaq minimum-bid threshold is a critical psychological and regulatory level, while the $2.79–$3.14 zone marked the stock's prior 52-week lows from May 2026 and represents overhead resistance. The long-term trend is firmly negative, with the shares down more than 80% over the past year.
Analyst price targets generally reflect a research horizon of roughly 12 months, though these particular targets are six months old and may not reflect the current situation. Investors should watch the HARMONIC trial protocol amendments and any FDA feedback, upcoming earnings and cash-burn disclosures, additional capital raises, and whether the company regains compliance with Nasdaq's minimum-bid requirement. Any analyst target revision — upward or downward — would be a key signal.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a highly volatile micro-cap like LTRN, such signals can help traders spot shifts in momentum and manage positions more efficiently than manual chart review alone. Traders can use the tool to discover opportunities, monitor existing holdings, and identify changing trends as they develop.
Can Lantern Pharma (LTRN) stock reach $17.50? The question is largely theoretical at present. The $17.50 figure is a legitimate arithmetic mean of two genuine analyst targets, but it was built on assumptions — and a share price near $3 — that no longer hold after the stock fell below $1 and received a delisting notice. The bull case rests on the LP-300 HARMONIC trial and the AI platform, which Lake Street's model values far above the current market cap. The bear case points to thin cash, ongoing losses, dilution risk, and the immediate question of Nasdaq compliance. With a 3,600% gap between price and target and only two, now-stale analyst forecasts, investors should treat $17.50 as a representation of an old, optimistic scenario rather than a near-term expectation, and monitor delisting status, clinical data, and financing above all else.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, LTRN has been loosely correlated with ALZN. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if LTRN jumps, then ALZN could also see price increases.
| Ticker / NAME | Correlation To LTRN | 1D Price Change % | ||
|---|---|---|---|---|
| LTRN | 100% | -22.70% | ||
| ALZN - LTRN | 38% Loosely correlated | -5.92% | ||
| WHWK - LTRN | 36% Loosely correlated | -4.35% | ||
| AXON - LTRN | 36% Loosely correlated | -0.21% | ||
| CGTX - LTRN | 34% Loosely correlated | -2.95% | ||
| CCCC - LTRN | 33% Loosely correlated | -4.76% | ||
More | ||||